Last reviewed · How we verify
Aminolaevulinic acid photodynamic therapy
Aminolaevulinic acid photodynamic therapy is a Photosensitizer Small molecule drug developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. It is currently in Phase 2 development for Actinic keratosis, Basal cell carcinoma.
Aminolaevulinic acid acts as a precursor to porphyrin, which accumulates in cancer cells and is activated by light to produce reactive oxygen species, inducing cell death.
Aminolaevulinic acid acts as a precursor to porphyrin, which accumulates in cancer cells and is activated by light to produce reactive oxygen species, inducing cell death. Used for Actinic keratosis, Basal cell carcinoma.
At a glance
| Generic name | Aminolaevulinic acid photodynamic therapy |
|---|---|
| Sponsor | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
| Drug class | Photosensitizer |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This mechanism is based on the principle of photodynamic therapy, where a photosensitizer is activated by light to produce reactive oxygen species, leading to cell death.
Approved indications
- Actinic keratosis
- Basal cell carcinoma
Common side effects
- Skin photosensitivity
- Skin rash
Key clinical trials
- Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer (PHASE1, PHASE2)
- Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection (NA)
- Photodynamic Therapy With Hydrogel Dressing for Chronic Wounds (NA)
- Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) (PHASE2)
- Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia (PHASE2)
- Photodynamic Therapy for Oral Precursor Lesions (PHASE3)
- Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors (PHASE1)
- A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aminolaevulinic acid photodynamic therapy CI brief — competitive landscape report
- Aminolaevulinic acid photodynamic therapy updates RSS · CI watch RSS
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Aminolaevulinic acid photodynamic therapy
What is Aminolaevulinic acid photodynamic therapy?
How does Aminolaevulinic acid photodynamic therapy work?
What is Aminolaevulinic acid photodynamic therapy used for?
Who makes Aminolaevulinic acid photodynamic therapy?
What drug class is Aminolaevulinic acid photodynamic therapy in?
What development phase is Aminolaevulinic acid photodynamic therapy in?
What are the side effects of Aminolaevulinic acid photodynamic therapy?
Related
- Drug class: All Photosensitizer drugs
- Manufacturer: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Actinic keratosis
- Indication: Drugs for Basal cell carcinoma
- Compare: Aminolaevulinic acid photodynamic therapy vs similar drugs
- Pricing: Aminolaevulinic acid photodynamic therapy cost, discount & access